ANZCTR search results

This research project is being conducted to determine whether treatment with Nasodine Nasal Spray reduces the severity of the common cold when given within 36 hours of symptom onset and over 5 consecutive days, multiple times a day.

The purpose of this project is to evaluate a digital version of an empirically supported group resilience-training program for adults living with multiple sclerosis (MS) called REsilience Activities every DaY (READY) for MS. The program was developed by researchers at University of Queensland (UQ) and is designed to teach resilience skills for managing life challenges. It is based on acceptance and commitment therapy (ACT), which is a recent variant of the well-established cognitive and behaviour therapy. The project involves a collaboration between UQ and two industry partners: a patient support organisation (Partizan Worldwide Pty Ltd) and a pharmaceutical company, Biogen Australia Pty Ltd. It is predicted that compared to people with MS on a waitlist, those who participate in the READY program will report significantly greater improvements in resilience, quality of life and distress.

This is an open-label study of adjunctive treatment with agomelatine in adults with major depressive disorder. This study aims to understand the biological correlates and consequences of agomelatine treatment.

Current research provides strong support that there is a relationship between sleep disturbances and developing many diseases, such as cardiovascular diseases and dementia. This highlights the key role of sleep monitoring in identifying important changes in individual’s sleep at a very early stage. The EMFIT QS (Quantified Sleep), an unobtrusive, contact-free sleep monitoring device, is used for tracking the changes in individual’s sleep. This device provides heart and respiration rate measurements, a sleep stage estimation, sleep quality analysis, and heart rate variability. This study is an open label pilot trial to determine sensor validation.

The last Adelaide Stroke Incidence Study (ASCEND) was carried out for 12 months between 2009 and 2010, sampling the western suburbs of Adelaide. We are 10 years on, and significant changes to the delivery model of stroke care in South Australia has occurred. Newer acute therapies and primary prevention methods, with shifting demographics make a repeat study necessary. A repeat population based study in South Australia (SA) will allow: 1. Identification of current Stroke incidence, outcome, recurrence rates and aetiology in SA. 2. Comparison to other Australian and International incidence studies – Are we still providing good quality care? 3. Comparison to initial ASCEND population – Are our primary prevention strategies well targeted? Is stroke incidence and aetiology evolving? Are risk profiles changing and are we managing risk better? 4. Evaluating future burden of stroke in SA for better directed resource allocation. 5. Identifying gaps in our current model of hyperacute stroke care provision. Are we missing out on revascularisation opportunities of Large Vessel occlusion strokes? 6. Understanding of how evolving demographics is modifying stroke incidence and risk profiles. 7. Comparison of Coded stroke aetiology to Trial of ORG 10172 in Acute Stroke Treatment (TOAST); Atherosclerosis, Small vessel disease, Cardioembolism, Other, Dissection (ASCOD) criteria and causative classification system (CCS) criteria. 8. Investigating the embolic stroke of undetermined source population for rates of symptomatic non-stenotic carotid disease (SyNC) to see if this may be a potential under-reported aetiology that warrants a different treatment paradigm. Expressed in the null, our main hypothesis is that in South Australia (SA), the age adjusted incidence of stroke will be similar to that reported 10 years ago in a similar population. In summary, a repeat Adelaide stroke incidence study, will allow an accurate contemporary classification of stroke incidence, risk profiles, subtypes and outcomes assisting in judicious delivery of primary prevention, hyperacute, subacute and rehabilitation stroke services in SA and nationally

The study aims to evaluate the use of acupuncture to reduce perceived stress levels in tertiary students. Participants will take part in four acupuncture interventions at either high or low frequency (once or twice per week). The study hopes to inform clinical decision making in practice. The hypothesis is that acupuncture is effective to reduce perceived stress, and that there is a difference (in both speed and size of effectiveness) between higher acupuncture treatment frequency than lower treatment frequency.

Vitamin D is a vitamin with roles in regulation of calcium and phosphate in the body and in bone health. It has also been found to regulate cell functions, including those of the immune system. Multiple sclerosis (MS) is one the most common disabling neurological conditions among young adults. Lower vitamin D levels are associated with a higher risk of developing MS. Our study aims to elucidate the effect that Vitamin D supplementation has on the immune cells firstly in healthy participants, following which we will aim to explore this in people with MS as well.

This aim of this study is to establish the efficacy for the first brief integrated intervention for parents of children with autism aged between 2 and 5 years 11 months of age. It will examine the following outcomes: 1) child externalising behaviours; 2) child social communication symptoms and adaptive functioning; and 3) parenting, parent-child interactions and parental wellbeing. It is hypothesised that at post, the intervention group, relative to the waitlist group, will have significantly lower levels of: 1) child externalising behaviour 2) child social and communication difficulties 3) dysfunctional parenting 4) parenting stress 5) inter-parental conflict. It is hypothesised that children who receive the intervention will have improved adaptive functioning and improved parent-child interaction at post-assessment, relative to the waitlist group. It is also hypothesised that the improvements across child and parent domains at post-intervention will be maintained at three-month follow-up for the intervention group.

The primary objective of this trial is to determine the feasibility of a pivotal clinical trial of intravenous iron and erythropoietin in adult survivors of critical illness requiring treatment in the intensive care unit. The hypothesis of the pilot phase of the trial is that a clinical trial of intravenous iron and erythropoietin is feasible based on the capacity of the study investigators to enrol sufficient eligible participants and deliver the study medications and follow up the patients appropriately. Demonstrating this would provide evidence that a trial with a much larger number of patients should be undertaken to assess safety and efficacy. The primary objective of the clinical phase of this trial is to determine the safety and efficacy of intravenous iron and erythropoietin in adult survivors of critical illness requiring treatment in the intensive care unit. In both phases the trial is parallel group, placebo-controlled, blinded, randomised trial that will allocate patients who are recovering in an ICU after an episode of critical illness and who are anaemic, in a 1:1 ratio, to intravenous iron and intravenous erythropoietin alfa in addition to standard care, or placebo in addition to standard care. The pilot phase was conducted at a single centre, the larger clinical trial is planned to be multicentre.

The TeleClinical Care-STOKE trial is a multicentre, prospective, randomised, blinded endpoint study. Patients discharged from hospital following an acute stroke/TIA will be randomised to management with the TCC-STROKE system or the standard of care for 6 months. The overall study aim is to demonstrate that a smartphone app-based system of transitional care following discharge from an acute stroke treatment centre can decrease hospital re-admission rates within six months. The primary hypothesis is that the TCC-STROKE system of transitional care will reduce the all cause hospital re-admission rate by 10%, relative to standard care, within six months of discharge following the index stroke event.